このページは機械翻訳されています。他のページは英語で表示される場合があります。 View in English

編集者訂正: ライフタイムと細胞ベースのインターセプティブ医療による欧州の医療の改善

Nikolaus Rajewsky ^1,2,3,4, Geneviève Almouzni ⁵, Stanislaw A Gorski ⁶

¹Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany. rajewsky@mdc-berlin.de.
²Charité-Universitätsmedizin, Berlin, Germany. rajewsky@mdc-berlin.de.
³Berlin Institute of Health (BIH), Berlin, Germany. rajewsky@mdc-berlin.de.
⁴German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany. rajewsky@mdc-berlin.de.
⁵Institut Curie, CNRS, PSL Research University, Sorbonne Université, Nuclear Dynamics Unit, Equipe Labellisée Ligue contre le cancer, Paris, France. genevieve.almouzni@curie.fr.
⁶Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany. stan.gorski@mdc-berlin.de.
⁷VIB Center for Brain and Disease Research, Leuven, Belgium.
⁸Department of Human Genetics, KU Leuven, Leuven, Belgium.
⁹Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
¹⁰Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Barcelona, Spain.
¹¹CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
¹²Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
¹³Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria.
¹⁴Department of Medical Humanities, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
¹⁵Institute of Human Genetics, UMR 9002, CNRS and University of Montpellier, Montpellier, France.
¹⁶Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
¹⁷Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), Utrecht, The Netherlands.
¹⁸University Medical Center Utrecht, Utrecht, The Netherlands.
¹⁹Oncode Institute, Utrecht, The Netherlands.
²⁰The Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
²¹Department of Neurosciences, KU Leuven, Leuven, Belgium.
²²UK Dementia Research Institute at UCL, University College London, London, UK.
²³Berlin Institute of Health (BIH), Berlin, Germany.
²⁴Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
²⁵Cell Biology and Biophysics Unit, European Molecular Biology Laboratory, Heidelberg, Germany.
²⁶Institut Curie, PSL Research University, Paris, France.
²⁷Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
²⁸Institute of Computing Science, Poznan University of Technology, Poznan, Poland.
²⁹Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
³⁰Faculty of Natural Sciences, University of Basel, Basel, Switzerland.
³¹Charité-Universitätsmedizin, Berlin, Germany.
³²German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.
³³Cardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
³⁴Department of Molecular Biology and Genetics (MBG), Aarhus University, Aarhus, Denmark.
³⁵Interdisciplinary Nanoscience Centre (iNANO), Aarhus University, Aarhus, Denmark.
³⁶Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.
³⁷Medical University of Vienna, Vienna, Austria.
³⁸Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
³⁹Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁴⁰Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
⁴¹Science for Life Laboratory, Stockholm, Sweden.
⁴²Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, KU Leuven, Leuven, Belgium.
⁴³Department of Oncology, KU Leuven, Leuven, Belgium.
⁴⁴European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.
⁴⁵Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
⁴⁶Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
⁴⁷CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain.
⁴⁸Universitat Pompeu Fabra, Barcelona, Spain.
⁴⁹ICREA, Barcelona, Spain.
⁵⁰Department of Internal Medicine, Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
⁵¹Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
⁵²Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany.
⁵³Centre de Biochimie Structurale, CNRS UMR 5048, INSERM U1054, Université de Montpellier, Montpellier, France.
⁵⁴VIB Technology Watch, Ghent, Belgium.
⁵⁵Department of Molecular Medicine, University of Padua School of Medicine, Padua, Italy.
⁵⁶IFOM, The FIRC Institute of Molecular Oncology, Padua, Italy.
⁵⁷Institut Curie, CNRS, PSL Research University, Sorbonne Université, Nuclear Dynamics Unit, Equipe Labellisée Ligue contre le cancer, Paris, France.
⁵⁸Institute for Biology, Humboldt University of Berlin, Berlin, Germany.
⁵⁹Epigenetics Programme, Babraham Institute, Cambridge, UK.
⁶⁰Centre for Trophoblast Research, University of Cambridge, Cambridge, UK.
⁶¹Department of Translational Research, Institut Curie, PSL Research University, Paris, France.
⁶²Institute of Clinical Molecular Biology, Kiel University, Kiel, Germany.
⁶³University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
⁶⁴German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
⁶⁵PRECISE, Platform for Single Cell Genomics and Epigenomics at the German Center for Neurodegenerative Diseases and the University of Bonn, Bonn, Germany.
⁶⁶Division of Computational Genomics and Systems Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁶⁷Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany.
⁶⁸Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, Israel.
⁶⁹Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.
⁷⁰Human Technopole, Milan, Italy.
⁷¹Biomedical Research Foundation, Academy of Athens, Athens, Greece.
⁷²Institute of Computational Biology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany.
⁷³Department of Mathematics, Technical University of Munich, Munich, Germany.
⁷⁴Institute of Epigenetics and Stem Cells (IES), Helmholtz Zentrum München - German Research Center for Environmental Health, Munich, Germany.
⁷⁵Faculty of Biology, Ludwig-Maximilians Universität, Munich, Germany.
⁷⁶Barcelona Supercomputing Center (BSC), Barcelona, Spain.
⁷⁷CNRS UMR3244, Institut Curie, PSL University, Paris, France.

⁰Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany. rajewsky@mdc-berlin.de.

Nature +

|

2021年3月18日

まとめ

No abstract available on PubMed

関連する概念動画

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

iPSCs have been successfully used to treat age-related macular degeneration (AMD), a form of...

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...